REVIEW PAPER
The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer
Submission date: 2016-07-18
Final revision date: 2017-02-05
Acceptance date: 2017-02-14
Publication date: 2018-03-30
Cent Eur J Immunol 2018;43(1):109-113
KEYWORDS
ABSTRACT
Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide. In Poland, colorectal cancer ranks second in tumor incidence regardless of sex; moreover, there has been a steady increase in the incidence of CRC. CRC results from complex interactions between inherited susceptibility, clinical conditions and environmental/lifestyle-related risk factors such as physical inactivity, smoking, alcohol consumption, high-fat/low-fiber diet, and obesity/overweight. The activation of pathways associated with insulin resistance and insulin-like growth factors (IGF) appears to be the epidemiological link between the metabolic syndrome and the development of CRC, which is of particular importance. What is significantly associated with the pathway of IGF is ADAM12 and 28-protein, which belong to a broad family of the adamalysines. These proteins, by adjusting the bioavailability of growth factors, influence the process of carcinogenesis. The aim of this article is to analyze the role of selected adamalysines and activation of the IGF system associated with the formation of colon cancer.
REFERENCES (42)
1.
Siegel R, Naishadham D, Jemal A (2013): Cancer statistics, 2013. CA Cancer J Clin 63: 11-13.
2.
Purim O, Gordon N, Brenner B (2013): Cancer of the colon and rectum: Potential effects of sex-age interactions on incidence and outcome. Med Sci Monit 19: 203-209.
3.
Nowakowska-Zajdel E, Wierzchowiec O, Kokot T, et al. (2013): Metabolic Abnormalities in Colorectal Cancer Patients. J Endocrinol Metab 2: 135-138.
4.
Fernandez E, Gallus S, Vecchia C, et al. (2004): Family History and Environmental Risk Factors for Colon Cancer. Cancer Epidemiol, Biomarkers Prev 13: 658-662.
5.
Cowey S, Hardy RW (2006): The metabolic syndrome. A high-risk state of cancer? Am J Pathol 169: 1505-1509.
6.
Wolpin BM, Meyerhardt JA, Chan AT, et al. (2009): Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. J Clin Oncol 27: 176-185.
7.
Muc-Wierzgoń M, Nowakowska-Zajdel E, Dzięgielewska-Gęsiak S (2014): Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J Gastroenterol 20: 9759-9774.
8.
Prieto-Hontoria PL, Prez-Matute P, Fernndez-Galilea M, et al. (2011): Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach. Biochim Biophys Acta 1807: 664-678.
9.
Riondino S, Roselli M, Palmirotta R, et al. (2014): Obesity and colorectal cancer: Role of adipokines in tumor initiation and progression. World J Gastroenterol 20: 5177-5190.
10.
Stocks T, Lukanova A, Bjørge T, et al. (2011): Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 117: 2398-2407.
11.
Benjamin M, Thomas M (2015): Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 6: 1246-1258.
12.
Yuhara H, Steinmaus C, Cohen SE, et al. ( 2011): Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol 106: 1911-1921.
13.
Jarvandi S, Davidson NO, Schootman M (2013): Increased Risk of Colorectal Cancer in Type 2 Diabetes Is Independent of Diet Quality. PLoS One 8: e74616.
14.
Kuroda H, Mochizuki S, Shimoda S, et al. (2010): ADAM28 is a serological and histochemical marker for non- small cell lung carcinoma. Int J Cancer 127: 1844-1856.
15.
Bowers LW, Rossi EL, O’Flanagan CH, et al. (2015): The role of the insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link. Front Endocrinol 6: 77.
16.
Zhan J, O’Brien C, Savage H, et al. (2009): Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 8: 2110-2121.
17.
Malagularnera R, Belfiore A (2014): The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol 5: 10.
18.
Pollak M (2012): The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature Rev Cancer 12: 159-169.
19.
Gallagher EJ, LeRoith D (2010): The Proliferating Role of Insulin and Insulin-Like Growth Factors in Cancer. Trends Endocrinol Metab 21: 610-618.
20.
Zhang L, Smith D, Gardinier B, et al. (2013): Modelling the Insulin Growth factor System in Articular cartilage. PLoS One 8: e66870.
21.
Vigneri PG, Tirro E, Pennisi MS, et al. (2015): The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy. Front Oncol 5: 230.
22.
Trajkovic-Arsic M, Kalideris E, Siveke JT (2013): The role of insulin and IGF system in pancreatic cancer. J Mol Endocrinol 50: 67-74.
23.
Nowakowska-Zajdel E, Mazurek U, Ziółko E, et al. (2011): Analysis of expression profile of gene encoding proteins of signal cascades activated by insulin-like growth factors in colorectal cancer. Int J Immunopathol Pharmacol 24: 781-787.
24.
Mochizuki S, Okada J (2007): ADAMs in cancer cell proliferation and progression. Cancer Sci 98: 621-628.
25.
Nowakowska-Zajdel E, Mazurek U, Wierzgoń J (2013): Expression of ADAM28 and IGFBP-3 genes in patients with colorectal cancer – a preliminary report. Int J Immunopathol Pharmacol 26: 223-228.
26.
Loechel F, Fox JW, Murphy G (2001): ADAM 12-S Cleaves IGFBP-3 and IGFBP-5 and Is Inhibited by TIMP-3. Biochem Biophys Res Comm 280: 421-429.
27.
Mitsui Y, Mochizuki S, Kodama T, et al. (2006): Adam 28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res 66: 9913-9920.
28.
Lazonschi L, Sunamura M, Kobari M, et al. (1999): Controlling tumor angiogenesis and metastais of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59: 1252-1258.
29.
Duffy MJ, McKiernan E, O’Donovan N, et al. (2009): Role of ADAMs in cancer formation and progression. Clin Canc Res 15: 1140-1144.
30.
Merchant NB, Voskresensky I, Rogers CM, et al. (2008): TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 14: 1182-1191.
31.
Kyula JN, Van Schaeybroeck S, Doherty J (2010): Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res 16: 3378-3389.
32.
Hirao T, Nanba D, Tanaka M, et al. (2006): Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res 312: 331-339.
33.
Gavert N, Ben-Ze’ev A (2007): Beta-Catenin signaling in biological control and cancer. J Cell Biochem 102: 820-828.
34.
Leszczyński P, Hendrich AB, Szmida E, Sąsiadek MM (2013): ADAM and ADAMTS family proteins and their role in colorectal cancer etiopathogenesis. BMB Reports 46: 139-150.
35.
Renehan AG, Frystyk J, Flyvbjerg A (2006): Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17: 328-336.
36.
Doyle SL, Donohoe CL, Lysaght J, et al. (2012): Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 71: 181-189.
37.
Jowett JB, Okada Y, Leedman PJ, et al. (2012): ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-. Immunol Cell Biol 90: 966-973.
38.
Menghini R, Fiorentino L, Casagrande V, et al. (2013): The role of ADAM17 in metabolic inflammation. Atherosclerosis 228: 12-17.
39.
Masaki M, Kurisaki T, Shirakawa K, et al. (2005): Role of meltrin {alpha} (ADAM12) in obesity induced by high-fat diet. Endocrinology 146: 1752-1763.
40.
Duffy MJ, Mullooly M, O’Donovan N, et al. (2011): The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clinical Proteinomics 8: 9.
41.
Fleck R, Bach D (2012): Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective. J Pers Med 2: 15-34.
42.
King ER, Kwong-Kwok W (2012): Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy. Recent Pat Anticancer Drug Discov 7: 14-30.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
